Meanwhile, Biocon, Cipla, Sun Pharma, Lupin, and Alkem are all in various stages of development or filing
Oral GLP-1 weight loss medication Orfoglipron (Eli Lilly) is nearing an FDA decision with available expect mid-2026 Clinical trials show meaningful results: 12-16% 1,2 average weight loss, which is slightly less than injectables Side effects are similar: mostly gastrointestinal, such as nausea or diarrhea, typically improving over 23 months
29.Friml, J., Benkova, E., Blilou, I., Wisniewska, J., Hamann, T., Ljung, K., Woody, S., Sandberg, G., Scheres, B., Jurgens, G., and Palme, K
For instance, engineered zinc-based nanoparticles such as zinc ferrite cores conjugated with disease-targeting moieties have been investigated for their ability to selectively deliver zinc into inflamed or dysfunctional cells, triggering organelle-specific responses
Taken together, these findings suggest thatcontrary to initial assumptionscomplex II may contribute to ferroptosis not by protecting cells via ubiquinol (CoQ 10 H 2 ) production but by promoting mitochondrial ROS accumulation
